Phase 3 Readout
CLDX: Phase 3 Topline: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Ba
April 1, 2027. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- April 1, 2027
- Company
- Celldex Therapeutics, Inc. (CLDX)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Ba
- Indication
- Chronic Spontaneous Urticaria